RxDoctor Payments Data

Sameh Hanna, MD

Pulmonary Disease · San Bernardino, CANPI 1326112913

Payments from drug & device makers

$16,540in general payments, 2019–2025

Across 73 payments — averaging $226.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$10K
  • Covidien LP$2K
  • US Endoscopy$2K
  • Pulmonx Corporation$1K
  • Steris Corporation$974
  • Merit Medical Systems Inc$245
  • plus $59 from 2 others

What the payments were for

  • Speaking & faculty fees$3002%
  • Travel & lodging$8,28450%
  • Food & beverage$1,95712%
  • Education$6,00036%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,540 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$36,441
Medicare patients
100
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate14$181,515
Dupixent PenDupilumab22$81,280
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$80,857
Spiriva RespimatTiotropium Bromide25$13,921
Spiriva HandihalerTiotropium Bromide14$8,618
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$7,094
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$5,052
Albuterol Sulfate HfaAlbuterol Sulfate61$1,970
Wixela InhubFluticasone Propion/Salmeterol19$1,423
Roflumilast18$1,039
Montelukast Sodium67$584
Fluticasone Propionate16$311
Furosemide30$131
Prednisone37$91
Azithromycin15$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$14$80,857113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →